Introduction
============

As the second leading cause of cancer-associated mortality, hepatocellular carcinoma (HCC) is one of the most prevalent types of cancer worldwide ([@b1-ol-0-0-9627]). The incidence rates of HCC have increased over the past two decades, with \>40,000 cases occurring in 2017 in the United States alone ([@b2-ol-0-0-9627]). The majority of patients with HCC do not receive early treatment and have a poor long-term overall survival (OS) rate, due to malignant features, such as late-stage presentation, metastasis, migration and the lack of HCC symptoms and specific biomarkers ([@b3-ol-0-0-9627]). Therefore, the diagnosis of HCC prior to reaching the advanced stage of the disease is imperative, in order to achieve improved treatment outcomes for patients. Currently, α-fetoprotein (AFP) is most widely used diagnostic serological marker for HCC ([@b4-ol-0-0-9627]). However, the expression of AFP is not specific to HCC, since it is also expressed in patients with chronic hepatitis B infection without HCC ([@b5-ol-0-0-9627]). Nevertheless, AFP-positivity is prevalently manifested in HCC tumors of large size, in the middle to advanced Tumor-Node-Metastasis stage and of high pathological grade compared with AFP-negative status. Therefore, the accuracy of serum AFP for the detection of early-stage HCC is limited ([@b6-ol-0-0-9627],[@b7-ol-0-0-9627]). Molecular targeted drugs have become clinically available, however, only a limited group of patients benefit from this treatment, due to their high price, unclear efficacy and variation in patient response ([@b8-ol-0-0-9627],[@b9-ol-0-0-9627]). Therefore, a more precise marker is urgently required for the early detection of HCC and the development of novel therapeutic approaches.

Intracellular communication, gene dysregulation and environmental factors have been indicated to be involved in the extremely complex underlying mechanisms of occurrence, advancement and metastasis of HCC ([@b10-ol-0-0-9627],[@b11-ol-0-0-9627]). From a molecular perspective, it has been indicated that multiple genes and cellular pathways take part in the origin and development of HCC ([@b12-ol-0-0-9627],[@b13-ol-0-0-9627]). MicroRNAs (miRNAs) are small non-coding endogenous RNAs, \~22 nucleotides in length, serving important roles in proliferation, differentiation, apoptosis, invasion and metastasis, as well as numerous other cellular biological processes ([@b14-ol-0-0-9627],[@b15-ol-0-0-9627]). It has been reported that numerous miRNAs exhibit different expression levels in various types of cancer, indicating their future clinical diagnostic value ([@b16-ol-0-0-9627]). Among them, miRNA-21 (miR-21) has been indicated to be overexpressed in mammalian cells and has been extensively examined in numerous types of cancer, including esophageal cancer, lung adenocarcinoma, pancreatic adenocarcinoma and tongue squamous cell carcinoma ([@b17-ol-0-0-9627]--[@b21-ol-0-0-9627]). A number of studies have reported the diagnostic value of elevated expression of miR-21 in HCC compared with healthy controls or patients with chronic hepatitis B infection ([@b22-ol-0-0-9627]--[@b25-ol-0-0-9627]).

High-throughput technologies, including microarrays and RNA sequencing, have served a crucial role in global gene expression research. The application of gene chip-based gene expression profiles has generated extensive information and provided a theoretical insight into the carcinogenesis of HCC. The Gene Expression Omnibus (GEO), as well as The Cancer Genome Atlas (TCGA), are public data portals regarding numerous cancer and non-cancerous samples, providing an unprecedented source of tumor-associated information for the identification of novel biomarkers. The development of natural language processing (NLP) has also been significant, focusing on the interactions between natural languages and computers and containing a large amount of laboratory and clinical data. The underlying biological mechanism of hub genes can be analyzed through Gene Ontology (GO) functional annotation, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and protein-protein interaction (PPI) network analysis. To the best of our knowledge, the limitation of previous studies regarding miRNA in HCC is their sole focus on serum, plasma, blood or tissue samples ([@b26-ol-0-0-9627],[@b27-ol-0-0-9627]).

In the present study, a comprehensive analysis was performed by combining literature studies, KEGG analysis, the GEO database, online software platforms and NLP. In addition, functional annotation and signaling pathway analyses of possible genes were performed with GO enrichment analysis, KEGG analysis and PPI networks. Subsequently, genes with the highest PPI scores were further investigated ([Fig. 1](#f1-ol-0-0-9627){ref-type="fig"}). The aim of the present study was to further understand the underlying pathogenic mechanism and potential clinical value of miR-21-5p in HCC, in order to provide precise diagnostic insights for HCC.

Materials and methods
=====================

Meta-analysis of the literature regarding the clinical role of miR-21-5p
------------------------------------------------------------------------

### Data acquisition

HCC-associated miR-21-5p data were collected from 14 databases: PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), Embase ([www.elsevier.com/solutions/embase-biomedical-research](www.elsevier.com/solutions/embase-biomedical-research)), EBSCO (<http://search.ebscohost.com>), Wiley Online Library (<http://onlinelibrary.wiley.com>), Science Direct (<https://www.sciencedirect.com/>), Web of Science (<http://webofknowledge.com/WOS>), Cochrane Central Register of Controlled Trials (<http://cochranelibrary-wiley.com/cochranelibrary/search?searchRow.searchOptions.searchProducts=clinicalTrialsDoi>), Ovid (<http://gateway.ovid.com/>), LILACS (<http://lilacs.bvsalud.org/en/>), Google Scholar ([scholar.google.com.cn/](scholar.google.com.cn/)), Chinese Chong Qing VIP (<http://qikan.cqvip.com/>), China National Knowledge Infrastructure (CNKI) (<http://www.cnki.com.cn>), Chinese Wan Fang database (<http://med.wanfangdata.com.cn/>) and China Biology Medicine disc (<http://www.sinomed.ac.cn/>). The literature searches of the present study were restricted to human studies. In order to acquire all relevant studies, the references of review papers and other relevant studies were also manually searched. Literature sources were retrieved from July 9 to September 8 2017 without restrictions on language. As miR-21-5p has been also referred to as miR-21, the key words and medical subject headings (MeSH) included the following: (miR-21 OR miRNA-21 OR microRNA-21 OR miR21 OR miRNA21 OR microRNA21 OR 'miR 21' OR 'miRNA-21' OR 'microRNA 21' OR miR-21-5p OR miR-21-5p OR microRNA-21-5p) AND (malignan\* OR cancer OR tumor OR tumour OR neoplas\* OR carcinoma) AND (hepatocellular OR liver OR hepatic OR HCC).

### Inclusion and exclusion criteria

A study was incorporated when it matched the filter criteria: i) An interpretation of the expression level of miR-21-5p in patients with HCC; ii) number of cases was reported in the study; iii) histopathological examination was used for diagnosis, iv) values of expression available directly or indirectly. Additionally, the following conditions caused the exclusion of a study: i) Duplicate publications; ii) failure to specify the control groups; iii) non-human subjects or, iv) lack of original data, such as review, case report or conference note.

### Collection and analysis of GEO data

GEO series (GSE) studies were gathered from the GEO database (<https://www.ncbi.nlm.nih.gov/geo/>). The information obtained included the expression profile of miR-21-5p, the fold-change value in HCC and the type of control sample. There was no restriction on the specific type of control group. Cell line assays or assays not considering expression were excluded. The following information was recorded for GSE chips: Main contributor (first author), publishing year, country, sample type, experiment type, the platform of the GSE chips and the number of patients with HCC and control patients. True positive (TP), false positive (FP), false negative (FN), true negative (TN) rates and area under the curve (AUC) were also recorded. All the expression values of miR-21-5p from GEO data were log2 scaled. The level of expression of miR-21-5p between patients with HCC and controls was compared using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA).

### Collection and clinical parameter analysis of TCGA data

TCGA miR-seq data was downloaded from Firebrowse (<http://firebrowse.org/>), for the entry of liver HCC ('LIHC') on April 17th, 2017. Subsequently, the data was manipulated by SPSS 21.0 (IBM Corp., Armonk, NY, USA). Clinical parameters, including age, sex, grade, stage, vascular invasion, history of primary risk factors, hepatitis B virus infection and histological type, were visualized using GraphPad Prism 5.0.

### Comprehensive meta-analysis based on studies from literature, GEO and TCGA

Consistent data elements for the integrated meta-analysis were extracted. Following the input of accuracy data, including TP, FP, FN and TN, of each study into MetaDiSc 1.4, the integrated value of sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and AUC was calculated ([@b28-ol-0-0-9627]). Receiver operator characteristic (ROC) curve was applied to evaluate the overall diagnostic accuracy. AUC was calculated for the combined pool of comprehensive data. Depending on the use of a healthy control group or chronic hepatitis B infection control group from the extracted studies, two additional analyses were performed in addition to the meta-analysis of the literature.

### Subgroup analyses

In order to evaluate the diagnostic capacity of miR-21-5p from different experimental methods and sample types and figure out the heterogeneity, four subgroup analyses were performed. Diagnostic efficiency of each subgroup was performed with MetaDiSc 1.4.

Potential target gene collection and bioinformatics investigation
-----------------------------------------------------------------

### Collection of potential target genes

Genes were selected when identified by \>3 of the 14 online software packages (miRanda, mirbridge, miRWalk, Microt4, mirTarbase, PITA, miRDB, RNA22, miRNAMap, miRMap, RNAhybrid, PicTar, Targetscan and PolymiRTS). Overlapping genes were identified by the combination of the predicted genes from 14 online software packages, TCGA, GEO and NLP. Overlapping genes were considered to be possible target genes of miR-21-5p.

### Functional annotation

GO functional annotation were performed and visualized by Bingo plug-in units from Cytoscape 3.5.0 (Cytoscape, Seattle, WA, USA) ([@b29-ol-0-0-9627]). GO pathway enrichment analysis consists of three components: i) Biological process (BP); ii) molecular function (MF), and iii) cellular component (CC). A BP term with P\<0.005 was considered to be statistically significant. P\<0.05 was denoted as the cut-off criteria for CC and MF terms. The functional annotation data were extracted from the downloaded files on August 31th, 2018.

### PPI network construction and signal pathway analyses

A bioinformatics database called Search Tool for the Retrieval of Interacting Genes/Proteins (STRING 10.5; <http://www.string-db.org>) was applied to establish a gene interaction network and excavate notable pathways associated with the potential target genes of miR-21-5p ([@b30-ol-0-0-9627]). KEGG pathways were determined from the Analysis module and the complete PPI network was drawn on August 31th, 2018. Each internal node in the PPI map represents one potential gene, while the edges between genes indicate a regulatory connection between the genes. These connections can be vividly synthesized and scored. The higher the score, the closer the association between the genes. Genes with high scores may occupy a critical position in the network or act as hub genes. A false discovery rate (FDR) \<0.05 value was regarded as the cut-off criteria for pathways by KEGG pathway analysis.

### Diagnostic values of hub genes

In order to investigate the association between the five hub genes and the progression of HCC, expression level in para-HCC non-cancerous tissues and HCC tissues (data from TCGA) was compared by single-sample t-test and ROC analysis. The degree of diagnostic value was assessed by the AUC of each gene. Correlation analysis of the hub genes and miR-21-5p expression was further established using Pearson correlation coefficient. GraphPad Prism software was utilized to generate scatter diagrams and visualize associations.

### Statistical analysis

Cochran *Q*-test and the inconsistency index (*I*^2^) was calculated to evaluate the heterogeneity. *I*^2^ \>50% and/or *P*\<0.05 was considered to indicate that heterogeneity existed in the study and the random-effects model was accepted. Otherwise, a fixed-effects model was used for statistical purposes ([@b31-ol-0-0-9627],[@b32-ol-0-0-9627]). The area under the sROC curve was used to evaluate the diagnostic value of miR-21-5p in HCC. The diagnosis information from the literature data and comprehensive data were recorded separately. The diagnostic efficiency of each meta-analysis was performed with MetaDiSc 1.4. P\<0.05 was considered to indicate a statistically significant difference. The potential publication bias was investigated with Deeks funnel plot asymmetry test.

Results
=======

### Meta-analysis of the literature regarding the clinical role of miR-21-5p

By retrieving and complying with the inclusion and exclusion criteria, 13 eligible studies were incorporated into the meta-analysis of the literature ([@b33-ol-0-0-9627]--[@b39-ol-0-0-9627]) ([Table I](#tI-ol-0-0-9627){ref-type="table"}). The flowchart indicated in [Fig. 2](#f2-ol-0-0-9627){ref-type="fig"} illustrates the selection and retrieval process. A total of 7 studies were performed in China, 3 in Egypt and 3 in Japan. The literature data were entered into MetaDiSc 1.4 and it was indicated that there was significant heterogeneity in the pooled estimates of SEN, SPE, PLR, NLR, and DOR, P\<0.05. Therefore, the random-effects model was used. The pooled sensitivity and specificity were 0.81 (95% confidence interval; (CI), 0.79--0.83) and 0.82 (95% CI, 0.80--0.85). The forest plots also revealed that the pooled PLR, NLR and DOR were 4.56 (95% CI, 3.29--6.31), 0.21 (95% CI, 0.15--0.30) and 24.56 (95% CI, 13.85--43.54), respectively. The sROC demonstrated an AUC of 0.904 from the 13 studies for the literature meta-analysis ([Table II](#tII-ol-0-0-9627){ref-type="table"}; [Fig. 3A](#f3-ol-0-0-9627){ref-type="fig"}). Consequently, the SEN, SPE, PLR, NLR and DOR of the healthy control group were 0.87 (95% CI, 0.83--0.90), 0.82 (95% CI, 0.77--0.86), 6.62 (95% CI, 2.48--15.63), 0.17 (95% CI, 0.10--0.29) and 39.09 (95% CI, 9.98--154.03), respectively ([Table II](#tII-ol-0-0-9627){ref-type="table"}). Correspondingly, the SEN, SPE, PLR, NLR and DOR of the chronic hepatitis B patient group were 0.75 (95% CI, 0.71--0.79), 0.84 (95% CI, 0.78--0.88), 4.36 (95% CI, 3.23--5.88), 0.27 (95% CI, 0.16--0.45) and 18.66 (95% CI, 7.89--44.15), respectively ([Table II](#tII-ol-0-0-9627){ref-type="table"}). The sROC demonstrated an AUC of 0.926 and 0.904 from the healthy control group and chronic hepatitis B patient group ([Table II](#tII-ol-0-0-9627){ref-type="table"}; [Fig. 3B and C](#f3-ol-0-0-9627){ref-type="fig"}).

### Collection and analysis of GEO data

Gene expression in HCC samples and corresponding adjacent para-tumorous liver tissues were compared. A total of 10 GSE chips from GEO datasets were available for the comprehensive meta-analysis ([@b40-ol-0-0-9627]--[@b46-ol-0-0-9627]) ([Table I](#tI-ol-0-0-9627){ref-type="table"}). A total of 8 chips were sequenced by array, while 2 chips were analyzed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). With the exception of one chip that used serum, the samples for the other 9 chips were tissue samples. Expression differed among the chips. Significant differences were observed in 5 GSE chips, which indicated increased expression of miR-21-5p in HCC tissues compared with the corresponding adjacent non-cancerous tissues (P\<0.05). The results were as follows: 2.55±0.0299 vs. 2.16±0.0176 (GSE22058; P\<0.0001; [Fig. 4A](#f4-ol-0-0-9627){ref-type="fig"}), 14.28±0.7054 vs. 12.97±0.2419 (GSE21279; P=0.0398; [Fig. 4B](#f4-ol-0-0-9627){ref-type="fig"}), 5.34±0.1105 vs. 2.30±0.3856 (GSE67882; P=0.0003; [Fig. 4C](#f4-ol-0-0-9627){ref-type="fig"}), 9.35±0.5412 vs. 5.46±0.2113 (GSE69580, P=0.0002, [Fig. 4D](#f4-ol-0-0-9627){ref-type="fig"}) and 14.70±0.0877 vs. 14.28±0.1655 (GSE12717; P=0.0268; [Fig. 4E](#f4-ol-0-0-9627){ref-type="fig"}). No statistically significant difference between HCC tissues and the adjacent non-cancerous tissues was indicated in the other 5 GSE chips. The results for these chips were as follows: 13.93±0.1315 vs. 13.97±0.1231 (GSE10694; P=0.8232; [Fig. 4F](#f4-ol-0-0-9627){ref-type="fig"}), 1.40±0.4191 vs. 0.83±0.1376 (GSE41874; P=0.3174; [Fig. 4G](#f4-ol-0-0-9627){ref-type="fig"}), 1.46±0.8684 vs. 0.57±0.1082 (GSE57555; P=0.0880; [Fig. 4H](#f4-ol-0-0-9627){ref-type="fig"}), 0.27±0.0401 vs. 0.20±0.0394 (GSE54751; P=0.2343; [Fig. 4I](#f4-ol-0-0-9627){ref-type="fig"}) and 1.917±0.9283 vs. 0.55±0.1955 (GSE50013; P=0.2534; [Fig. 4J](#f4-ol-0-0-9627){ref-type="fig"}).

### Collection of clinicopathological characteristics from TCGA

A total of 9 clinicopathological characteristics were associated with miR-21-5p expression level. Significant overexpression of miR-21-5p was observed in HCC tissues (19.95±1.0672), compared with the non-cancerous tissues (18.67±0.7504; P\<0.0001; [Fig. 5A](#f5-ol-0-0-9627){ref-type="fig"}). Increased expression of miR-21-5p was identified for advanced tumor grade stage III--IV (20.10±0.0840) compared with early tumor grade stage I--II (19.84±0.0735) (P=0.0215; [Fig. 5B](#f5-ol-0-0-9627){ref-type="fig"}). miR-21-5p differential expression was associated with history of primary risk factors. Factors, hepatitis B virus (HBV)-infected, alcohol consumption and nonalcoholic fatty liver disease, defined 'positive', and 'negative' was defined as no history of risk factors. Significant differences were observed between positive (19.73±0.1328) and negative (20.02±0.0811) (P=0.0475; [Fig. 5C](#f5-ol-0-0-9627){ref-type="fig"}). HBV-infected patients exhibited a significantly increased expression level (20.15±0.0865) compared with HBV-negative patients (19.84±0.0723) (P=0.0125; [Fig. 5D](#f5-ol-0-0-9627){ref-type="fig"}). Increased expression level of miR-21-5p was identified in HCC tumors (20.88±0.3447) compared with other histological types of liver such as hepatocholangiocarcinoma and fibrolamellar carcinoma (19.91±0.0565) (P=0.0047; [Fig. 5E](#f5-ol-0-0-9627){ref-type="fig"}). No significant differences in miR-21-5p expression level were associated with vascular invasion, stage, age or sex ([Fig. 5F-I](#f5-ol-0-0-9627){ref-type="fig"}).

### Integrated diagnostic value

A total of 24 studies, including 10 microarrays from GEO datasets, 13 literature studies and TCGA-based RNA sequencing data were included for the comprehensive meta-analysis. Significant heterogeneity was identified in all five pooled effects (SEN, SPE, PLR, NLR and DOR) by the *Q* and *I*^2^ tests (all *I*^2^ \>50% and *P*\<0.05). Accordingly, a random-effects model was employed. As presented in [Table II](#tII-ol-0-0-9627){ref-type="table"}, the overall SEN, SPE, PLR, NLR and DOR of the studies were 0.78 (95% CI, 0.76--0.80), 0.79 (95% CI, 0.77--0.82), 4.46 (95% CI, 2.91--6.84), 0.26 (95% CI, 0.20--0.33) and 20.17 (95% CI, 11.65--34.92), respectively. The AUC value of integrated meta-analysis was 0.887 ([Fig. 3D](#f3-ol-0-0-9627){ref-type="fig"}).

### Subgroup analyses

Subgroup analyses based on experiment type (RT-qPCR or array) and sample type (tissue or serum/plasma) were conducted. For the experiment type subgroups, the SEN, SPE, PLR, NLR and DOR of the RT-qPCR subgroup were 0.81 (95% CI, 0.79--0.83), 0.82 (95% CI, 0.79--0.84), 4.12 (95% CI, 3.02--5.61), 0.22 (95% CI, 0.15--0.30) and 22.00 (95% CI, 12.73--38.01), respectively. The corresponding 5 values in the array subgroup were 0.77 (95% CI, 0.71--0.83), 0.68 (95% CI, 0.61--0.74), 4.57 (95% CI, 1.30--16.06), 0.39 (95% CI, 0.24--0.64) and 15.70 (95% CI, 3.32--74.29) ([Table III](#tIII-ol-0-0-9627){ref-type="table"}). The values of SEN, SPE and DOR were markedly increased in the RT-qPCR subgroup compared with the array subgroup. For the subgroup analysis of different sample types, the SEN, SPE, PLR, NLR and DOR of the tissue subgroup were 0.73 (95% CI, 0.69--0.76), 0.72 (95% CI, 0.67--0.77), 4.35 (95% CI, 1.66--11.39), 0.36 (95% CI, 0.28--0.47) and 15.24 (95% CI, 5.00--45.45). The SEN, SPE, PLR, NLR and DOR in the serum/plasma subgroup were 0.81 (95% CI, 0.79--0.83), 0.82 (95% CI, 0.79--0.85), 4.44 (95% CI, 3.16--6.25), 0.21 (95% CI, 0.15--0.30) and 23.99 (95% CI, 13.27--43.37) ([Table III](#tIII-ol-0-0-9627){ref-type="table"}). The value of SEN, SPE, PLR and DOR were increased in the serum/plasma subgroup compared with the tissue subgroup. AUC values from the sROC of the RT-qPCR subgroup, array subgroup, tissue subgroup and serum/plasma subgroup were 0.896, 0.822, 0.826 and 0.902, respectively ([Table III](#tIII-ol-0-0-9627){ref-type="table"}; [Fig. 3](#f3-ol-0-0-9627){ref-type="fig"}). Nevertheless, no publication bias existed in the meta-analysis according to Deeks test. (P=0.877; [Fig. 6](#f6-ol-0-0-9627){ref-type="fig"}).

Potential target gene collection and bioinformatics analysis
------------------------------------------------------------

### Collection of prospective target genes

A total of 48,446 target genes were identified from 14 prediction software packages and genes had to be identified ≥3 times to be regarded as potential target genes of miR-21-5p. Reduced-expression genes assembled from TCGA and GEO and genes selected from NLP were integrated to identify overlapping genes. Out of the 10,911 potential target genes, 1,123 reduced-expression genes from TCGA, 2,956 reduced-expression genes from GEO and 1,800 genes were analyzed for intersection. This resulted in 39 target genes attained for the following bioinformatics analyses.

### Functional annotation and signal pathway analyses

The GO annotation system in DAVID identified the 39 target genes significantly involved in the following biological processes: 'response to chemical stimulus' (GO:0042221; P=2.08×10^−11^), 'regulation of MAPKKK cascade' (GO:0043408; P=1.68×10^−10^) and 'regulation of intracellular protein kinase cascade' (GO:0010627; P=2.39×10^−10^) ([Table IV](#tIV-ol-0-0-9627){ref-type="table"}; [Fig. 7](#f7-ol-0-0-9627){ref-type="fig"}). As for cellular components, target genes were concentrated in terms of the 'cell surface' (GO:0009986; P=9.04×10^−7^), 'interleukin-6 receptor complex' (GO:0005896; P=1.57×10^−5^) and 'plasma membrane part' (GO:0044459; P=8.66×10^−5^) ([Table IV](#tIV-ol-0-0-9627){ref-type="table"}; [Fig. 8](#f8-ol-0-0-9627){ref-type="fig"}). The ten significant GO terms were exhibited for BP, CC and MF.

Genes were prominently accumulated in 3 molecular functions, including 'growth factor binding' (GO:0019838; P=2.10×10^−7^), 'caffeine oxidase activity' (GO:0034875; P=3.53×10^−5^) and 'oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor' (GO:0033695; P=3.53×10^−5^ ([Table IV](#tIV-ol-0-0-9627){ref-type="table"}; [Fig. 9](#f9-ol-0-0-9627){ref-type="fig"}). Additionally, five pathways took precedence in KEGG pathway analysis (FDR\<0.01): 'Cytokine-cytokine receptor interaction' (hsa04060; FDR=0.00262), 'Rap1 signaling pathway' (hsa04015; FDR=0.00393), 'PI3K-Akt signaling pathway' (hsa04151; FDR=0.00393), 'Malaria' (hsa05144; FDR=0.00659) and 'MicroRNAs in cancer' (hsa05206; FDR=0.00894) ([Table V](#tV-ol-0-0-9627){ref-type="table"}).

### PPI network construction

The PPI network indicating the interactions between 39 target genes of miR-21-5p is demonstrated by 39 nodes and 36 edges in [Fig. 10](#f10-ol-0-0-9627){ref-type="fig"}. A total of 5 hub genes were identified according to their scores, including HGF, FOXO1, THBS1, ESR1 and CXCL12.

### Diagnostic values of the 5 hub genes

Significantly increased expression of HGF was observed in normal controls (10.19±0.13) compared with patients with HCC (7.45±0.23) (P\<0.001; [Fig. 11Aa](#f11-ol-0-0-9627){ref-type="fig"}). Similarly, the FOXO1 expression level was significantly increased in normal controls (11.36±0.11) compared with patients with HCC (10.15±0.13) (P\<0.001; [Fig. 11Ab](#f11-ol-0-0-9627){ref-type="fig"}). Patients with HCC had a significantly decreased THBS1 expression level (11.57±0.24) compared with healthy controls (13.09±0.18) (P\<0.001; [Fig. 11Ac](#f11-ol-0-0-9627){ref-type="fig"}). Expression of ESR1 was significantly increased in normal controls (10.51±0.10) compared with patients with HCC (7.52±0.33) (P\<0.001; [Fig. 11Ad](#f11-ol-0-0-9627){ref-type="fig"}). Significantly increased CXCL12 expression level was observed in normal controls (13.18±0.10) compared with patients with HCC (10.15±0.25) P\<0.001; [Fig. 11Ae](#f11-ol-0-0-9627){ref-type="fig"}). The AUCs of HGF, FOXO1, THBS1, ESR1 and CXCL12 were 0.9437 (95% CI, 0.9220--0.9654; P\<0.0001; [Fig. 11Ba](#f11-ol-0-0-9627){ref-type="fig"}), 0.9232 (95% CI, 0.8951--0.9513; P\<0.0001; [Fig. 11Bb](#f11-ol-0-0-9627){ref-type="fig"}), 0.8686 (95% CI, 0.8258--0.9114; P\<0.0001; [Fig. 11Bc](#f11-ol-0-0-9627){ref-type="fig"}), 0.9511 (95% CI, 0.9299--0.9724; P\<0.0001; [Fig. 11Bd](#f11-ol-0-0-9627){ref-type="fig"}) and 0.9816 (95% CI, 0.9705--0.9927; P\<0.0001; [Fig. 11Be](#f11-ol-0-0-9627){ref-type="fig"}), respectively. The results of correlation analysis between the hub genes (HGF, FOXO1, THBS1, ESR1 and CXCL12) and miR-21-5p were as follows: (R=0.01851; P=0.08995; [Fig. 11Ca](#f11-ol-0-0-9627){ref-type="fig"}), (R=−0.3467; P=0.0147; [Fig. 11Cb](#f11-ol-0-0-9627){ref-type="fig"}), (R=0.4334; P=0.0019; [Fig. 11Cc](#f11-ol-0-0-9627){ref-type="fig"}), (R=−0.4129; P=0.0032; [Fig. 11Cd](#f11-ol-0-0-9627){ref-type="fig"}), (R=0.3830; P=0.0066; [Fig. 11Ce](#f11-ol-0-0-9627){ref-type="fig"}), respectively.

Discussion
==========

The pathogenesis of HCC has been extensively investigated and there is a consensus that miRNAs may act as vital diagnostic markers for the detection of multiple types of malignancy. In particular, miR-21-5p, located on chromosome 17q23.1, has been reported to be implicated in cancer diagnosis and prognosis ([@b47-ol-0-0-9627],[@b48-ol-0-0-9627]). Numerous previous studies have investigated the underlying functional mechanism of miR-21-5p in numerous types of tumor. Wu *et al* ([@b49-ol-0-0-9627]), Zeng *et al* ([@b50-ol-0-0-9627]), Qu *et al* ([@b51-ol-0-0-9627]) and Markou *et al* ([@b52-ol-0-0-9627]) have investigated miR-2-5p in colorectal cancer, gastric cancer, pancreatic cancer and non-small cell lung cancer, respectively. Previous studies have also reported a decrease in tumor-cell proliferation, migration and invasion following the knockdown of miR-21-5p expression in HCC cells ([@b53-ol-0-0-9627],[@b54-ol-0-0-9627]). Tomimaru *et al* demonstrated that the ROC analysis of plasma miR-21 yielded an AUC of 0.953 (87.3% sensitivity and 92.0% specificity) for differentiating HCC from healthy participants. In addition, when distinguishing between liver cancer and chronic hepatitis, plasma miR-21 yielded an AUC of 0.773 (83.3% specificity and 61.1% sensitivity) ([@b37-ol-0-0-9627]). This meta-analysis of integrated studies from literature, GEO and TCGA demonstrated appreciable diagnostic significance of miR-21-5p for HCC. Studies based on RT-qPCR and serum/plasma have been identified to have improved diagnostic value compared with the array and tissue studies. Furthermore, the detection of miR-21 expression from serum/plasma is non-invasive, making it more applicable in a clinical setting.

In previous studies, miR-21-5p diagnostic ability has been reported, due to an increased level of expression being correlated with HBV infection, advanced tumor grade, history of risk factors and advanced pathological stage. HBV infection is considered to be a major risk factor for hepatocarcinogenesis ([@b55-ol-0-0-9627]). However, the underlying mechanism of miRNAs with HBV-associated HCC requires further investigation. Xie *et al* have identified certain factors contributing to HCC, including long-term HBV infection, high levels of HBV replication, HBV genotype, specific HBV variants, HBV integration and HBV coding proteins ([@b56-ol-0-0-9627]). Xie *et al* ([@b57-ol-0-0-9627]) have summarized the change in expression of numerous miRNAs in HBV infection and have demonstrated the upregulation of miR-21 expression in HBV-associated HCC. In the present study, a more accurate diagnostic effect of miR-21-5p was demonstrated in distinguishing patients with HCC from a healthy population (AUC=0.926) compared with patients from chronic HBV (AUC=0.904). The result further verified the elevated expression of miR-21-5p in HBV-associated HCC.

A total of 5 hub genes (HGF, FOXO1, THBS1, ESR1 and CXCL12) were identified by PPI network construction. It should be noted that FOXO1 and ESR1 were negatively correlated with miR-21-5p. Forkhead box O1 (FOXO1 or FKHR) has been reported to be the target gene of miR-21 in various types of tumor, including large B-cell lymphoma, pancreatic ductal adenocarcinoma and glioblastoma ([@b58-ol-0-0-9627]--[@b60-ol-0-0-9627]). The aforementioned studies have identified that overexpression of miR-21 decreased the level of FOXO1. Dong *et al* have claimed that FOXO1 inhibits the invasion and metastasis of HCC ([@b61-ol-0-0-9627]). However, the specific function of FOXO1 in HCC has not yet been determined. The role of estrogen receptor 1 (ESR1) in breast cancer has been investigated, but also its clinical relevance in prostate, endometrial and other types of cancer ([@b62-ol-0-0-9627]). The expression of ESR1 can predict the grade and stage of non-muscle-invasive bladder carcinoma have been reported ([@b63-ol-0-0-9627]). Dou *et al* have stated that methylation of ESR1 in HBV-associated HCC may be affected by HBV ([@b64-ol-0-0-9627]). A study by Hishida *et al* ([@b65-ol-0-0-9627]) considered ESR1 as a candidate tumor suppressor gene in HCC. THBS1 may serve a role as an inhibitor of tumor growth, cell migration and neovascularization in lung cancer ([@b66-ol-0-0-9627]). From the functional annotation analysis in the present study, the hub genes participated in various processes, including 'response to chemical stimulus', 'cell surface' and 'growth factor binding'. It was speculated that miR-21-5p expression may be involved in metabolism or apoptotic processes of HCC.

While the present study provides additional evidence supporting the use of miR-21-5p to diagnose HCC, there are limitations that should be acknowledged. Firstly, significant heterogeneity was unavoidable. As noted in the meta-analysis, samples from serum or plasma and the use of RT-qPCR were more precise in diagnosing HCC compared with studies using tissues or the array method, which indicated that the sample type and experiment type may influence the accuracy of diagnosis. Secondly, variation in sample size, sex ratio and age may also have contributed to heterogeneity. Thirdly, miR-21-5p expression levels in patients with HCC from different geographic locations and times may also have an effect. In addition, the results were based solely on data from a range of databases. Therefore, verification experiments to reveal the underlying molecular mechanisms of miR-21-5p are required to confirm the results of the present study, particularly the pathway and functional analysis of miR-21-5p.

In conclusion, an accumulation of data from GEO datasets, TCGA, NLP and literature databases was performed to describe the application potential of miR-21-5p in HCC. Using bioinformatics methods, including pathway enrichment analyses, functional annotation by GO and correlation analysis, the underlying molecular mechanism of miR-21-5p was investigated. Subgroup analyses for different types of experiment and sample were also conducted, in order to compare the diagnostic capacity and identify sources of heterogeneity. FOXO1 and ESR1 were negatively correlated with upregulation of miR-21-5p expression. The highest enriched pathway (cytokine-cytokine receptor interaction) requires further investigation. Prospective studies with large cohorts are required to verify the present study\'s findings, and to clarify the underlying molecular mechanism of miR-21-5p in HCC.
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![Flow chart of the study protocol. HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; GEO, Gene Expression Omnibus; GO, Gene Ontology; PPI, protein-protein interaction network; NLP, Natural Language Processing; sROC, summary receiver operating characteristic.](ol-17-01-0230-g00){#f1-ol-0-0-9627}

![Flow chart indicating the identification of qualified studies for miR-21-5p as a diagnostic marker for HCC. HCC, hepatocellular carcinoma.](ol-17-01-0230-g01){#f2-ol-0-0-9627}

![The sROC analysis of miR-21-5p expression. (A) Healthy control group. (B) Chronic hepatitis B control group. (C) Integrated studies. (D) RT-qPCR subgroup. (E) Array subgroup. (F) Tissue subgroup. (G) Serum subgroup. (H) Plasma subgroup. sROC, summary receiver operating characteristic; AUC, area underthe curve; RT-qPCR, reverse transcriptase-quantitative polymerase chain reaction; miR, microRNA.](ol-17-01-0230-g02){#f3-ol-0-0-9627}

![The expression level of miR-21-5p in HCC tissues and adjacent non-cancerous tissues from GEO data. (A) GSE22058. (B) GSE21279. (C) GSE67882. (D) GSE69580. (E) GSE12717. (F) GSE10694. (G) GSE41874. (H) GSE57555. (I) GSE54751. (J) GSE50013. HCC, hepatocellular carcinoma; GEO, Gene Expression Omnibus; miR, microRNA.](ol-17-01-0230-g03){#f4-ol-0-0-9627}

![The expression level of miR-21-5p according to clinicopathological parameters in HCC from TCGA data. (A) Normal control and HCC. (B) Grade. (C) History of primary risk factors. (D) Hepatitis B virus infection. (E) Histological type. (F) Vascular invasion. (G) Stage. (H) Age. (I) Sex. HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; miR, microRNA.](ol-17-01-0230-g04){#f5-ol-0-0-9627}

![The publication bias of miR-21-5p, based on the comprehensive meta-analysis. ESS, effective sample size; miR, microRNA.](ol-17-01-0230-g05){#f6-ol-0-0-9627}

![Directed acyclic graph of pathways identified by GO analysis from the perspective of BP. Each node represents a specific GO term of a BP (P\<0.005). BP, biological process; GO, Gene Ontology.](ol-17-01-0230-g06){#f7-ol-0-0-9627}

![Directed acyclic graph of pathways identified by GO analysis from the perspective of CC. Each node represents a specific GO term of a CC (P\<0.05). CC, cellular component; GO, Gene Ontology.](ol-17-01-0230-g07){#f8-ol-0-0-9627}

![Directed acyclic graph of pathways identified by GO analysis from the perspective of MF. Each node represents a specific GO term of a MF (P\<0.05). NADH, nicotinamide adenine dinucleotide; NADPH, nicotinamide adenine dinucleotide phosphate; ATP, adenosine triphosphate; MF, molecular function; GO, gene ontology.](ol-17-01-0230-g08){#f9-ol-0-0-9627}

![The protein-protein interaction network of the target genes of miR-21-5p.](ol-17-01-0230-g09){#f10-ol-0-0-9627}

![Expression levels, ROC curves and correlation analysis of the 5 hub genes. (A) Expression levels of (a) HGF, (b) FOXO1, (c) THBS1, (d) ESR1 and (e) CXCL12 in HCC tissues and non-cancerous tissues from TCGA data. (B) ROC curves of (a) HGF, (b) FOXO1, (c) THBS1, (d) ESR1 and (e) CXCL12 in HCC from TCGA data. (C) Correlation analysis of (a) HGF, (b) FOXO1, (c) THBS1, (d) ESR1 and (e) CXCL12 and miR-21-5p from TCGA data. HCC, hepatocellular carcinoma; TCGA, The Cancer Genome Atlas; ROC, receiver operating characteristic; HGF, hepatocyte growth factor; FOXO1, forkhead box 1; THBS1, thrombospondin 1; ESR1, estrogen receptor 1; CXCL12, C-X-C motif chemokine ligand 12.](ol-17-01-0230-g10){#f11-ol-0-0-9627}

###### 

Information and clinical data on the 24 included studies.

  Accession       First author            Publication year   Country   Experiment type                     Platform   Sample type   Number of patients with HCC   Control patients   TP    FP   FN    TN    AUC     (Refs.)
  --------------- ----------------------- ------------------ --------- ----------------------------------- ---------- ------------- ----------------------------- ------------------ ----- ---- ----- ----- ------- ----------------------
  PMID:21229610   Xu *et al* (a)          2011               China     RT-qPCR                                        Serum         101                           89                 85    24   16    65    0.870   ([@b33-ol-0-0-9627])
  PMID:22403344   Liu *et al* (c)         2012               China     RT-qPCR                                        Serum         57                            59                 51    17   6     42    0.865   ([@b34-ol-0-0-9627])
  PMID:26302751   Amr *et al* (b)         2015               Egypt     RT-qPCR                                        Serum         23                            17                 23    3    0     14    0.943   ([@b35-ol-0-0-9627])
  PMID:26669589   Zhuang *et al* (a)      2015               China     RT-qPCR                                        Serum         52                            43                 35    17   11    24    0.621   ([@b36-ol-0-0-9627])
  PMID:27113935   El-Tawdi *et al* (a)    2016               Egypt     RT-qPCR                                        Serum         78                            42                 73    2    5     40    0.957   ([@b14-ol-0-0-9627])
  PMID:27113935   El-Tawdi *et al* (b)    2016               Egypt     RT-qPCR                                        Serum         78                            36                 73    4    5     32    0.938   ([@b14-ol-0-0-9627])
  PMID:21749846   Tomimaru *et al* (a)    2012               Japan     RT-qPCR                                        Plasma        126                           50                 110   4    16    46    0.953   ([@b37-ol-0-0-9627])
  PMID:21749846   Tomimaru *et al* (b)    2012               Japan     RT-qPCR                                        Plasma        126                           30                 77    5    49    25    0.773   ([@b37-ol-0-0-9627])
  PMID:21283620   Mizuguchi *et al* (b)   2011               Japan     RT-qPCR                                        Tissue        22                            22                 17    6    5     16    0.780   ([@b38-ol-0-0-9627])
  PMID:28477010   Guo *et al* (b)         2017               China     RT-qPCR                                        Serum         175                           64                 135   9    40    55    0.789   ([@b24-ol-0-0-9627])
  PMID:28477010   Guo *et al* (c)         2017               China     RT-qPCR                                        Serum         175                           278                144   45   31    233   0.849   ([@b24-ol-0-0-9627])
  CNKI            Qin *et al* (a)         2013               China     RT-qPCR                                        Plasma        55                            50                 48    3    7     47    0.956   ([@b39-ol-0-0-9627])
  CNKI            Qin *et al* (b)         2014               China     RT-qPCR                                        Plasma        55                            60                 34    10   21    50    0.771   ([@b39-ol-0-0-9627])
  GSE22058        Burchard *et al*        2010               USA       Non-coding RNA profiling by array   GPL10457   Tissue        96                            96                 71    7    25    89    0.877   ([@b40-ol-0-0-9627])
  GSE10694        Li *et al*              2008               China     Non-coding RNA profiling by array   GPL6542    Tissue        78                            88                 61    62   17    26    0.506   ([@b41-ol-0-0-9627])
  GSE41874        Morita *et al*          2013               Japan     Non-coding RNA profiling by array   GPL7722    Tissue        6                             4                  3     0    3     4     0.625   --
  GSE21279        Hou *et al*             2010               China     Non-coding RNA profiling by array   GPL9052    Tissue        4                             11                 3     1    1     10    0.841   ([@b42-ol-0-0-9627])
  GSE57555        Murakami *et al*        2015               Japan     Non-coding RNA profiling by array   GPL16699   Tissue        5                             16                 3     4    2     12    0.625   ([@b43-ol-0-0-9627])
  GSE67882        Ghosh *et al*           2015               India     Non-coding RNA profiling by array   GPL10850   Tissue        4                             8                  4     0    0     8     1.000   --
  GSE69580        Hung *et al*            2015               China     Non-coding RNA profiling by array   GPL10850   Tissue        5                             5                  5     0    0     5     1.000   --
  GSE12717        Su et al                2008               China     Non-coding RNA profiling by array   GPL7274    Tissue        10                            6                  10    2    0     4     0.800   ([@b44-ol-0-0-9627])
  GSE54751        Zhao et al              2014               USA       Expression profiling by RT-qPCR     GPL18262   Tissue        10                            10                 9     4    1     6     0.710   ([@b45-ol-0-0-9627])
  GSE50013        Shen et al              2013               USA       Expression profiling by RT-qPCR     GPL15497   Plasma        12                            8                  9     4    3     5     0.615   ([@b46-ol-0-0-9627])
  TCGA                                                                                                                Tissue        375                           50                 260   3    115   47    0.840   

GO, Gene Ontology; HCC, hepatocellular carcinoma; AUC, area under the curve; TP, true positive; FP, false positive; FN, false negative; TN, true negative; RT-qPCR, reverse transcriptase-quantitative polymerase chain reaction, (a), healthy control group; (b), control group with chronic hepatitis B infection; (c), non-cancerous control group (healthy and chronic hepatitis B carriers); TCGA, The Cancer Genome Atlas.

###### 

Summary estimates of diagnostic criteria and the 95% confidence intervals.

  Analysis               Literature studies     Control group: Healthy   Control group: CHB    Integrated studies
  ---------------------- ---------------------- ------------------------ --------------------- ----------------------
  Sensitivity (95% CI)   0.81 (0.79--0.83)      0.87 (0.83--0.90)        0.75 (0.71--0.79)     0.78 (0.76--0.80)
  Specificity (95% CI)   0.82 (0.80--0.85)      0.82 (0.77--0.86)        0.84 (0.78--0.88)     0.79 (0.77--0.82)
  Positive LR (95% CI)   4.56 (3.29--6.31)        6.22 (2.48--15.63)     4.36 (3.23--5.88)     4.46 (2.91--6.84)
  Negative LR (95% CI)   0.21 (0.15--0.30)      0.17 (0.10--0.29)        0.27 (0.16--0.45)     0.26 (0.20--0.33)
  DOR (95% CI)           24.56 (13.85--43.54)   39.09 (9.92--154.03)     18.66 (7.89--44.15)   20.17 (11.65--34.92)
  AUC                    0.904                  0.926                    0.904                 0.887

CI, confidence interval; LR, likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; CHB, chronic hepatitis B infection.

###### 

Summary estimates of diagnostic criteria and the 95% confidence intervals of four subgroups.

  Analysis               RT-qPCR subgroup       Non-coding RNA profiling by array subgroup   Tissue subgroup       Serum/plasma subgroup
  ---------------------- ---------------------- -------------------------------------------- --------------------- -----------------------
  Sensitivity (95% CI)   0.81 (0.79--0.83)      0.77 (0.71--0.83)                            0.73 (0.69--0.76)     0.81 (0.7869--0.83)
  Specificity (95% CI)   0.82 (0.79--0.84)      0.68 (0.61--0.74)                            0.72 (0.67--0.77)     0.82 (0.79--0.85)
  Positive LR (95% CI)   4.12 (3.02--5.61)      4.57 (1.30--16.06)                           4.35 (1.66--11.39)    4.44 (3.16--6.25)
  Negative LR (95% CI)   0.22 (0.15--0.30)      0.39 (0.24--0.64)                            0.36 (0.28--0.47)     0.21 (0.15--0.30)
  DOR (95% CI)           22.00 (12.73--38.01)   15.70 (3.32--74.29)                          15.24 (5.00--46.45)   23.99 (13.27--43.37)
  AUC                    0.896                  0.822                                        0.826                 0.902

CI, confidence interval; LR, likelihood ratio; DOR, diagnostic odds ratio; AUC, area under the curve; RT-qPCR, reverse transcriptase-quantitative polymerase chain reaction.

###### 

GO functional annotation of the target genes of miR-21-5p.

  GO ID        GO term                                                                                        Category   Count   P-value    Correlation P-value
  ------------ ---------------------------------------------------------------------------------------------- ---------- ------- ---------- ---------------------
  GO:0042221   Response to chemical stimulus                                                                  BP         20      2.08E-11   3.0689E-08
  GO:0043408   Regulation of MAPKKK cascade                                                                   BP         9       1.68E-10   1.173E-07
  GO:0010627   Regulation of intracellular protein kinase cascade                                             BP         11      2.39E-10   1.173E-07
  GO:0048518   Positive regulation of biological process                                                      BP         21      4.33E-09   1.2905E-06
  GO:0050896   Response to stimulus                                                                           BP         26      4.92E-09   1.2905E-06
  GO:0010648   Negative regulation of cell communication                                                      BP         10      5.26E-09   1.2905E-06
  GO:0042127   Regulation of cell proliferation                                                               BP         14      6.66E-09   1.4006E-06
  GO:0048523   Negative regulation of cellular process                                                        BP         19      1.09E-08   0.000002015
  GO:0009968   Negative regulation of signal transduction                                                     BP         7       1.77E-08   0.000002835
  GO:0023057   Negative regulation of signaling process                                                       BP         7       1.99E-08   0.000002835
  GO:0009986   Cell surface                                                                                   CC         8       9.04E-07   0.00010939
  GO:0005896   Interleukin-6 receptor complex                                                                 CC         2       1.57E-05   0.00095048
  GO:0044459   Plasma membrane part                                                                           CC         14      8.66E-05   0.0034849
  GO:0043235   Receptor complex                                                                               CC         4       1.15E-04   0.0034849
  GO:0005886   Plasma membrane                                                                                CC         19      2.19E-04   0.0040511
  GO:0005615   Extracellular space                                                                            CC         8       2.57E-04   0.0040511
  GO:0005887   Integral to plasma membrane                                                                    CC         10      2.61E-04   0.0040511
  GO:0009897   External side of plasma membrane                                                               CC         4       2.78E-04   0.0040511
  GO:0031226   Intrinsic to plasma membrane                                                                   CC         10      3.01E-04   0.0040511
  GO:0044421   Extracellular region part                                                                      CC         8       1.60E-03   0.019331
  GO:0019838   Growth factor binding                                                                          MF         6       2.10E-07   0.000056609
  GO:0034875   Caffeine oxidase activity                                                                      MF         2       3.53E-05   0.0031751
  GO:0033695   Oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor   MF         2       3.53E-05   0.0031751
  GO:0016725   Oxidoreductase activity, acting on CH or CH2 groups                                            MF         2       2.62E-04   0.017694
  GO:0005496   Steroid binding                                                                                MF         3       5.66E-04   0.023457
  GO:0051117   ATPase binding                                                                                 MF         2       6.07E-04   0.023457
  GO:0008083   Growth factor activity                                                                         MF         4       6.09E-04   0.023457
  GO:0060089   Molecular transducer activity                                                                  MF         13      1.17E-03   0.023457
  GO:0004871   Signal transducer activity                                                                     MF         13      1.17E-03   0.023457
  GO:0005125   Cytokine activity                                                                              MF         4       1.35E-03   0.023457

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

KEGG pathway analysis of the target genes of miR-21-5p.

  KEGG ID    Name                                      Count   FDR       Gene symbol
  ---------- ----------------------------------------- ------- --------- ----------------------------------------
  hsa04060   Cytokine-cytokine receptor interaction    6       0.00262   CCR1, CXCL12, HGF, IL6ST, NGFR, PDGFRA
  hsa04015   Rap1 signaling pathway                    5       0.00393   HGF, NGFR, PDGFRA, TEK, THBS1
  hsa04151   PI3K-Akt signaling pathway                6       0.00393   HGF, NGFR, PDGFRA, TEK, THBS1, TLR4
  hsa05144   Malaria                                   3       0.00659   HGF, THBS1, TLR4
  hsa05206   MicroRNAs in cancer                       4       0.00894   PDGFRA, SPRY2, THBS1, ZEB2
  hsa05202   Transcriptional misregulation in cancer   4       0.0126    DUSP6, FOXO1, IGFBP3, NGFR
  hsa05215   Prostate cancer                           3       0.0204    AR, FOXO1, PDGFRA
  hsa05323   Rheumatoid arthritis                      3       0.0204    CXCL12, TEK, TLR4
  hsa04014   Ras signaling pathway                     4       0.0225    HGF, NGFR, PDGFRA, TEK
  hsa05205   Proteoglycans in cancer                   4       0.0225    ESR1, HGF, THBS1, TLR4

KEGG, Kyoto Encyclopedia of Genes and Genomes; FDR, false discovery rate.
